ERBB2 and gastroesophageal junction adenocarcinoma: Another ongoing study (NCT02205047) is a randomized phase II trial investigating trastuzumab alone or in combination with pertuzumab as neoadjuvant therapy for HER‐2 positive gastric and GEJ adenocarcinoma.